A Phase 1, Open-Label, Multicenter, Dose Escalation Study of mRNA-2752, a Lipid Nanoparticle Encapsulating mRNAs Encoding Human OX40L, IL-23, and IL-36γ, for Intratumoral Injection Alone and in Combination with Immune Checkpoint Blockade

Principal Investigator

Shivaani Kummar

Study Purpose

The purpose of the study is to learn more about the investigational drug, mRNA-2752 (from here on, will be referred to as the study drug), in people with advanced cancer (advanced metastatic solid tumor malignancies or lymphoma). We are hoping to gather information on the safety, tolerability (good and bad effects), and effectiveness of the study drug in treating specific types of cancers. In this clinical research study, the study drug will either be given alone or given together with durvalumab.

Medical Condition(s)

Triple negative breast cancer
Head and neck squamous cell carcinoma
Non-Hodgkin’s lymphoma
Urothelial cancer

Eligibility Criteria

Individuals of 18 years of age and older.
Diagnosed with cancer mentioned in the previous list.

Age Range

18 - 100

Healthy Volunteers Needed


Duration of Participation

The length of your participation in this study will depend on how long you receive the study drug(s). This could range from 1 day to more than 24 months. In this study you may continue to be followed up to 180 days after you have received the last dose of the study drug(s) through telephone calls, medical record review, and/or clinic visits.

Minors Included



Knight Clinical Trials Information Line


Moderna Inc.

Recruitment End


Compensation Provided


Go Back